In conclusion, combining ribociclib with letrozole provided clinically meaningful improvements in progression-free survival, overall response rates, and clinical benefit rates and was well tolerated in patients with de novo advanced HR+, HER2− breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.